SynthesisRenal failure2025
Impact of polycystic kidney disease on outcomes after renal transplantation: systematic review and meta-analysis.
Synthesis in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic kidney disease (PKD) represents one of the most prevalent inherited renal disorders and constitutes the fourth leading etiology of end-stage kidney disease (ESKD). While renal transplantation remains the optimal therapeutic intervention for ESKD, existing evidence regarding post-transplant survival rates and graft loss in PKD recipients remains contentious. This systematic review incorporated studies from PubMed, Scopus, and Embase databases, with a preregistered protocol on PROSPERO (CRD420251002570). We evaluated the impact of PKD on post-transplant outcomes through comparative analyses of patient survival and graft survival at 1-, 5-, and 10-year intervals between PKD and non-PKD cohorts. Secondary outcomes included complication profiles. Methodological quality was appraised using the ROBINS-I tool for non-randomized studies. From 1,187 screened records, 23 studies were eligible for inclusion. Meta-analysis demonstrated superior 1-year patient survival in PKD kidney transplant recipients (OR 1.30, 95% CI: 1.08-1.56; 19 studies, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.